(175 days)
Not Found
No
The device description and performance studies focus on controlled heat delivery and clinical efficacy, with no mention of AI/ML algorithms, data processing, or training/test sets.
Yes
The device is indicated for the "treatment" of individual actic pimples in persons with mild to moderate inflammatory acne, which is a therapeutic purpose. It also describes a "treatment tip" and "clinical testing" for its effectiveness.
No
The device is indicated for treatment of acne, not for diagnosis.
No
The device description explicitly states it is a "portable hand-held device" that produces heat and has a "treatment tip" and is "powered by rechargeable AAA nickel-metal hydride batteries," indicating it is a hardware device, not software-only.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Zeno's Function: Zeno is a device that applies heat directly to the skin to treat acne. It does not analyze any biological samples taken from the body.
The description clearly states that Zeno is a "portable hand-held device that produces accurately controlled low level sustained heat for use in treating dermatological disorders, specifically, mild to moderate acne." This is a therapeutic device, not a diagnostic one.
N/A
Intended Use / Indications for Use
Zeno is indicated for the treatment of individual acne pimples in persons with mild to moderate inflammatory acne.
Product codes (comma separated list FDA assigned to the subject device)
GEX
Device Description
Zeno is a portable hand-held device that produces accurately controlled low level sustained heat for use in treating dermatological disorders, specifically, mild to moderate acne. Individual acne blemishes are treated for a preset time of 2 ½ minutes at a preset temperature. The treatment tip is made from a biocompatible material and delivers the specific low-level heat to the individual acne blemish. The device is powered by rechargeable AAA nickel-metal hydride batteries.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Zeno will be available over the counter (OTC) versus the predicate device which is prescription use only.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Preclinical and clinical testing performance testing was conducted with Zeno. In vitro testing demonstrated significant sensitivity of p. acnes bacterial colls to the effects of sustained low-level heat. Biocompatibility testing of the tip material was conducted in accordance with the ISO 10993 Biological Testing of Medical and Dental Materials and Devices and the tip material is considered biocompatible. Zeno was tested for EMI in accordance with the IEC 60601-1 standard. Zeno operates within the EMI emission, susceptibility and static discharge levels specified in the IEC 60601-1 standard. Clinical testing was conducted in both a controlled practitioner office environment and a consumer home-use environment and submitted as part of the 510(k) application to confirm that Zeno is as safe and effective as the predicate device. The controlled clinical study design was a randomized, doubled-blinded study.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three lines forming its body and wings. The eagle is facing to the right. The text "DEPARTMENT OF HEALTH AND HUMAN SERVICES U.S." is arranged in a circular pattern around the eagle.
JUL 1 3 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Tyrell, Inc. c/o Ms. Darla J. Elkin Director, Regulatory Affairs, Quality Systems Synergos, Incorporated 2202 Timberloch Place, Suite 230 The Woodlands, Texas 77380
Re: K043377 Trade/Device Name: Zeno Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: II Product Code: GEX Dated: March 2,2005 Received: March 3,2005
Dear Ms. Elkin:
This letter corrects our substantially equivalent letter of June 1,2005.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may. therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Page 2 - Ms. Darla J. Elkin
Please be advised that FDA's issuance of a substantial equivalencedeterminationdoes not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Miriam Provost, Ph..
Miriam Provost. Ph.D
Acting Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Enclosure
2
510(k) Premarket Notification Tyrell, Incorporated - Zeno™ Acne Device
Indications for Use
510(k) Number: K043377
Device Name: Zeno
Indications For Use: Zeao is indicated for the treatment of individual actic pimples in persons with mild to moderate inflammatory acne.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
( PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE F NEEDED |
Concurrence of CDRH, Office of Device Evaluation(ODE)
Z. Chin
Page 1 of 1
(.0.0)
List of General, Restorative
Neurological Devices
· · · · · . ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3
3
JUN 1 - 2005
510(k) Premarket Notification Tyrell, Incorporated Zeno™ Acne Device
510(k) SUMMARY TYRELL, INCORPORATED - Zeno Acne Device
This 510(k) Summary is submitted in accordance with 21 CFR Part 807, Section 807.92.
| Sponsor's Name and Address: | Tyrell, Inc.
515 West Greens Road, Suite 725
Houston, TX 77067 |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Telephone: (281) 880 - 6541
Facsimile No. (281) 880 - 6702 |
| Submittor Information: | Darla J. Elkin
Director, Regulatory Affairs, Quality Systems
SYNERGOS, Inc.
2202 Timberloch Place, Suite 230
The Woodlands, TX 77380-1109 |
| | Telephone No.: (281) 367-6655
Facsimile No.: (281) 367-9679 |
| Device Trade Name: | Zeno™ |
| Common Name: | Acne Treatment Device |
| Classification: | Class II |
| Predicate Devices: | National Biological Corporation
Derma-Wand
K982082 |
| | CureLight Ltd.
ClearLight Phototherapy System, Model CI 420
K013623 |
| | Radiancy (Israel) Ltd.
Radiancy Acne System With ClearTouch Light Unit A
K032205 |
Description of the Device
Zeno is a portable hand-held device that produces accurately controlled low level sustained heat for use in treating dermatological disorders, specifically, mild to moderate acne. Individual acne blemishes are treated for a preset time of 2 ½ minutes at a preset temperature. The treatment tip is made from a biocompatible material and delivers the specific low-level heat to the individual acne blemish. The device is powered by rechargeable AAA nickel-metal hydride batteries.
4
510(k) Premarket Notification Tyrell, Incorporated Zeno™ Acne Device
Indications for Use
Zeno is indicated for the treatment of individual acne pimples in persons with mild to moderate inflammatory acne.
Performance Data
Preclinical and clinical testing performance testing was conducted with Zeno.
Preclinical Testing
In vitro testing demonstrated significant sensitivity of p. acnes bacterial colls to the effects of sustained low-level heat.
Biocompatibility testing of the tip material was conducted in accordance with the ISO 10993 Biological Testing of Medical and Dental Materials and Devices and the tip material is considered biocompatible.
Zeno was tested for EMI in accordance with the IEC 60601-1 standard. Zeno operates within the EMI emission, susceptibility and static discharge levels specified in the IEC 60601-1 standard.
Clinical Testing
Clinical testing was conducted in both a controlled practitioner office environment and a consumer home-use environment and submitted as part of the 510(k) application to confirm that Zeno is as safe and effective as the predicate device. The controlled clinical study design was a randomized, doubled-blinded study.
Substantial Equivalence
The Zeno and its predicate devices are all devices that use either light or heat to treat the dermatological condition of mild to moderate acne by exposing the surface of the skin to the light at precise wavelengths and temperatures or heat at precise temperatures. Although there are differences in the technological characteristics of the Zeno and its predicate devices, those differences do not raise new questions of safety or efficacy. Another difference is Zeno will be available over the counter (OTC) versus the predicate device which is prescription use only however there are no new safety or efficacy concerns regarding this use as evidenced by the clinical testing that was conducted on Thus, Zeno is substantially equivalent to the predicate device for treatment of Zeno. mild to moderate acne.
Conclusion:
Based on the indications for use, technological characteristics, performance testing and comparison to predicate devices, the proposed device has been shown to be safe and effective for its intended use.